Veritas Therapeutics currently presents itself as a biotechnology company developing diagnostic and therapeutic technologies based on FGL2 biology for autoimmune disease. The company website emphasizes platform development rather than a broad commercial portfolio. Its positioning appears focused on translational research and the use of FGL2-based approaches in immune-mediated conditions.